Intas Pharmaceuticals Ltd.

15 patents currently held · Updated Nov 15, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Oct 2033

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jun 5, 2027
The maintenance fee for Extended release pharmaceutical composition of Clozapine (US 11,833,253) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
1 fee due Sep 5, 2027
The maintenance fee for Stable extended release pharmaceutical composition of clozapine (US 11,918,590) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
1 fee due Oct 19, 2027
The maintenance fee for Process for the preparation of fulvestrant (US 9,315,540) comes due Oct 19, 2027. Unpaid by Apr 19, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 of the patents on this record was granted since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,315,540	Process for the preparation of fulvestrant In force Term ends Oct 11, 2033 · From the USPTO record	In force	Term ends Oct 11, 2033	From the USPTO record
US 9,511,145	Stable tigecycline composition In force Term ends Mar 25, 2034 · From the USPTO record	In force	Term ends Mar 25, 2034	From the USPTO record
US 9,914,770	Cloning, expression and purification method for the preparation of ranibizumab In force Term ends Jul 7, 2034 · From the USPTO record	In force	Term ends Jul 7, 2034	From the USPTO record
US 10,052,361	Liquid pharmaceutical composition of conjugated erythropoietin In force Term ends Feb 27, 2035 · From the USPTO record	In force	Term ends Feb 27, 2035	From the USPTO record
US 10,918,698	Lyophilized Pharmaceutical Composition of Fc-Peptide Fusion Protein In force Term ends Dec 5, 2036 · High confidence	In force	Term ends Dec 5, 2036	High confidence
US 11,833,253	Extended release pharmaceutical composition of Clozapine In force Ends no later than Sep 16, 2037 · From the USPTO record	In force	Ends no later than Sep 16, 2037	From the USPTO record
US 11,504,336	Extended release pharmaceutical composition of clozapine In force Term ends Feb 18, 2038 · From the USPTO record	In force	Term ends Feb 18, 2038	From the USPTO record
US 11,433,058	Non-Pulsatile Prolonged-Release Betahistine Oral Solid Compositions In force Term ends Jan 26, 2039 · High confidence	In force	Term ends Jan 26, 2039	High confidence
US 11,648,207	An Extended Release Pharmaceutical Composition of Clozapine In force Term ends Apr 8, 2042 · High confidence	In force	Term ends Apr 8, 2042	High confidence
US 11,918,590	Stable extended release pharmaceutical composition of clozapine In force Ends no later than Apr 8, 2042 · From the USPTO record	In force	Ends no later than Apr 8, 2042	From the USPTO record

10 of 15 patents shown.

Pro members see all 15.

Pro members: see all 15 patents

Also on record, not counted in the 15: 4 lapsed for an unpaid fee · 1 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 2 abandoned · 21 no status recorded

List them